Bristol-Myers Squibb announces executive changes
NEW YORK Drug maker Bristol-Myers Squibb announced a wave of executive appointments Wednesday as part of what it called a transformation to a “next-generation” biopharmaceutical leader.
The company appointed Lamberto Andreotti as president and COO and elected him to the board of directors, also placing him on the newly formed executive committee with chairman and CEO James Cornelius. Elliott Sigal became EVP, chief science officer and president research and development and will oversee Bristol’s research, discovery and development functions. Jean-Marc Huet was promoted to EVP and CFO and will also oversee the areas of strategy and productivity.
“This group will chart the future for Bristol-Myers Squibb,” Cornelius said in a statement. “Our transformation over the past 15 months has been swift and seamless, and we will continue to move forward as a company purely focused on helping patients prevail against serious disease.”
Bristol also named Anthony Hooper as president for the Americas, Beatrice Cazala as president for global commercialization and Europe, John Celentano as president for emerging markets and the Asia-Pacific region, Giovanni Caforio as SVP global and United States oncology and Carlo De Notaristefani as president for technical operations and global support functions.
McKesson Canada withdraws acquisition offer
MONTREAL McKesson Canada has withdrawn its offer to take over Uniprix, the company has announced.
McKesson Canada said the number of shares tendered was not enough to meet the Jan. 19 acquisition offer’s conditions.
“Despite withdrawing our offer, McKesson Canada will continue to support the independent pharmacy business model,” McKesson Canada president Domenic Pilla said in a statement. “As such, our desire to help the Uniprix Group succeed and to see further growth among its banners remains strong, and we wish to pursue our longstanding business relationship.”
D&W Fresh Markets, Family Fare and VG’s Expand Discounted Generic Drug Program
GRAND RAPIDS, Mich. On March 1, D&W Fresh Market, Family Fare and VG’s pharmacies expanded their generic drug program to 90-day prescriptions for $10, the companies announced.
D&W Fresh Market, Family Fare and VG’s Pharmacies are also increasing the number of women’s health medications they offer at the discounted price. These include prescription drugs such as tamoxifen to treat breast cancer and pre-natal vitamins.
Presently, there are two programs offering lower prices on over 300 generic drugs to meet the healthcare needs and healthcare budgets of our customers. These pharmacies are also increasing the number of women’s health medications as part of the generic drug program offer.
This new initiative expands the program introduced in November 2008 that provides a $4 price for more than 300 generic drugs prescribed in 30-day supplies. It also complements several other programs these stores are offering customers to help them stretch their food, fuel, healthcare and household budgets cross promotions, bonus savings and other initiatives.
“Our expanded generic drug program is another example of the many ways we are making it easier for customers to stretch their food, healthcare, and household dollars,” said Alan Hartline, EVP mechandising. “Our customers can continue to rely on the expert health counsel and friendly service our team of professional pharmacists consistently offer.”